Treatment of bevacizumab-induced hypertension by amlodipine

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 702-707

  Mir, Olivier ^a   Coriat, Romain ^a   Ropert, Stanislas ^a   Cabanes, Laure ^b   Blanchet, Benoit ^b   Camps, Sandra ^b   Billemont, Bertrand ^a   Knebelmann, Bertrand ^c   Goldwasser, François ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b NONE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Amlodipine; Bevacizumab; Dose intensity; Hypertension; VEGF

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CISPLATIN; CLOPIDOGREL; FELODIPINE; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLATINUM COMPLEX; RAMIPRIL; ANGIOGENESIS INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASODILATOR AGENT; VEGFA PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HOARSENESS; HUMAN; HUMAN CELL; HYPERTENSION; HYPOTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; COLORECTAL TUMOR; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; FRANCE; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PARIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATOR AGENTS;

EID: 84861716353     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9549-5     Document Type: Article

References (23)

1. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20(5):807-815
2. Lee JB, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee ES, Kim YH, Kim JS, Seo JH (2009) Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and metaanalysis of randomized controlled trials. Invest New Drugs. doi:10.1007/s10637-009-9310-0
3. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23(5):460-468
4. Mir O, Ropert S, Alexandre J, Goldwasser F (2009) Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20(5):967-970
5. Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49(2):186-193
6. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232-1239
7. Monsuez JJ, Charniot JC, Vignat N, Artigou JY (2010) Cardiac side-effects of cancer chemotherapy. Int J Cardiol. doi:10.1016/j. ijcard.2010.03.003
8. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC et al: Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:1-9
9. Burris JF, Allenby KS, Mroczek WJ (1994) The effect of amlodipine on ambulatory blood pressure in hypertensive patients. Am J Cardiol 73(3):39A-43A
10. Burges R, Moisey D (1994) Unique pharmacologic properties of amlodipine. Am J Cardiol 73(3):2A-9A
11. Abernethy DR (1994) An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol 73(3):10A-17A
12. European Society of Hypertension-European Society of Cardiology Guidelines Committee (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21(6):1011-1053
13. O'Brien E (2003) Ambulatory blood pressure measurement is indispensable to good clinical practice. J Hypertens Suppl 21(2): S11-S18
14. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (3):176-181
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
16. Lowery M, Power D, Behbehani A, Carney D, Mc Caffrey JA (2007) Hypertension is a significant adverse effect of bevacizumab treatment. J Clin Oncol 25 (18S)(18S):Abstract 14134
17. Pande A, Lombardo J, Spangenthal E, Javle M (2007) Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 27(5B):3465-3470
18. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46(2):439-448
19. Wenzel RR (2005) Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 65(Suppl 2):29-39
20. Hedrick E, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Dong W, Suzuki S, Sugrue M, Grothey A (2006) Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). J Clin Oncol 24 (18S)(18S):Abstract 3536
21. Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A et al (2009) Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol 27(36):6152-6159
22. Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K (2005) Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res 28(2):147-153
23. Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B (2010) Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. doi:10.1007/s10637-010-9514-3